In the article “Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis” [Liver Cancer. 2025; https://doi.org/10.1159/000549955] by Chan et al., the copyright license has been changed to a CC-BY 4.0 license. The original online article has been updated to reflect this.
. 2026 May 27. Online ahead of print. doi: 10.1159/000552217
Erratum
© 2026 The Author(s). Published by S. Karger AG, Basel
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (https://karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
PMCID: PMC13215674 PMID: 42211893
This corrects the article "Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis" with doi: 10.1159/000549955.